Comparative Pharmacology
Head-to-head clinical analysis: ADVIL LIQUI GELS versus ANAPROX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL LIQUI GELS versus ANAPROX.
ADVIL LIQUI-GELS vs ANAPROX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and fever.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200–400 mg orally every 4–6 hours as needed; maximum 1200 mg/day.
250-500 mg orally twice daily; maximum 1.5 g/day; for extended-release: 375-750 mg orally twice daily
None Documented
None Documented
1.8 to 2.5 hours. The short half-life supports dosing every 4 to 6 hours for acute pain and fever.
Terminal elimination half-life 12-17 hours; prolonged in elderly (up to 20 hours) and in renal impairment.
Renal excretion of metabolites and conjugates accounts for approximately 90% of an administered dose. Less than 1% is excreted unchanged. Biliary/fecal elimination accounts for about 10%.
Renal excretion of metabolites (95%) and unchanged drug (<5%); biliary/fecal elimination minor (<5%).
Category C
Category C
NSAID
NSAID